Skip to main content

losmapimod

losmapimod: sourced relationships with 1 company · 3 clinical trials tracked.

losmapimod evidence translation

What we can confirm

What it means

Source-backed records connect losmapimod to FULC; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could losmapimod → FULC affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Facioscapulohumeral Muscular Dystrophy 1; Facioscapulohumeral Muscular Dystrophy (FSHD)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Fulcrum Therapeutics, Inc. (FULC)
licensee · Reported 2024-02-27 · Current development: unknownSource
Facioscapulohumeral Muscular Dystrophy 1; Facioscapulohumera…
Phase 3
Clinical Trial Registry Records (3)

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470Registry updated 2025-11-10·Phase 3·FULC
Terminated

Primary endpoint: Part A: Change From Baseline in Total Relative Surface Area (RSA) Quadrants 1 to 5 (Q1-Q5) With 500 Grams (g) Wrist Weight Averaged Over Both Arms as Assessed by Reachable Workspace (RWS) at Week 48

InterventionalRandomizedquadruple260 enrolledStarted 2022-06Completion 2024-1133 sites · Canada, Denmark, France, Germany…Fulcrum Therapeutics

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442Registry updated 2025-09-30·Phase 2·FULC
Terminated

Primary endpoint: Number of Participants Reporting Serious Treatment Emergent Adverse Events (Serious TEAEs) and TEAEs

Interventionalopen76 enrolledStarted 2020-02Completion 2024-1117 sites · Canada, France, Spain, United StatesFulcrum Therapeutics

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) With Extension

NCT04004000Registry updated 2025-12-02·Phase 2·FULC
Terminated

Primary endpoint: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

Interventionalopen14 enrolledStarted 2019-08Completion 2024-101 site · NetherlandsFulcrum Therapeutics

Frequently asked questions

Which companies have sourced relationships with losmapimod?

losmapimod has dated SEC/FDA relationship records for Fulcrum Therapeutics, Inc..

How many clinical trials involve losmapimod?

BioSniper tracks 3 clinical trials involving losmapimod.